Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Part of paid clinical trials in La Jolla, California.

Sponsor
Iovance Biotherapeutics, Inc.
Study ID
NCT03419559
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LN-145 — BIOLOGICAL
    adoptive cell therapy (ACT) with autologous TIL therapy
  • Durvalumab — DRUG
    PD-L1 antagonist monoclonal antibody

Study Details

This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT) with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.

Key Dates

Start date
Feb 28, 2018
Status verified
Apr 2019
Primary completion
Dec 31, 2021
Completion
Dec 31, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LN-145 in combination with durvalumab
    After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

Primary Outcome Measure

Objective Response Rate [ Time Frame: A maximum of 24 months ]

Locations (8)

FacilityCityStateZIPSite coordinators
University of California San Diego, Moores Cancer CenterLa JollaCalifornia92093-
University of California, Los Angeles, Santa Monica Hematology/OncologyLos AngelesCalifornia90095-
University of Louisville James Graham Brown Cancer CenterLouisvilleKentucky40202-
Karmanos Cancer InstituteDetroitMichigan48201-
Morristown Medical Center Atlantic Hematology OncologyMorristownNew Jersey07960-
UPMC Cancer CenterPittsburghPennsylvania15232-
Vanderbilt UniversityNashvilleTennessee37232-
University of Washington Medical CenterSeattleWashington98195-0001-

Find similar trials in La Jolla, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
University of California San Diego, Moores Cancer Center· La Jolla, CAUniversity of California, Los Angeles, Santa Monica Hematology/Oncology· Los Angeles, CAUniversity of Louisville James Graham Brown Cancer Center· Louisville, KYKarmanos Cancer Institute· Detroit, MIMorristown Medical Center Atlantic Hematology Oncology· Morristown, NJUPMC Cancer Center· Pittsburgh, PA

Related Studies